Korro Bio faces a precarious financial outlook as its reliance on sporadic milestone payments fails to offset consistent quarterly operating losses exceeding $20 million. The company's OPERA platform development requires significant capital, yet the erosion of...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$1.07+20.1% vs -$1.34 | $2M+600.0% vs $214,286 |
Q2 2026 May 7, 2026 | -$1.69-5.6% vs -$1.60 | — vs $761,167 |
Q2 2026 May 6, 2026 | -$1.69+2.1% vs -$1.73 | — vs $761,167 |
Q2 2026 Mar 12, 2026 | -$5.32-175.6% vs -$1.93 | $1M+85.7% vs $700,000 |
Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and three have given
CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to three newly hired employees.
CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences:
Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have issued a buy recommendation and three have assigned a
Benchmark KRRO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Korro Bio, Inc. (KRRO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.34 | $102.92M | -0.83 | 181.46% | -1834.48% | -110.7% | — | |
| $25.93 | $2.67B | -32.01 | 120.01% | -54.75% | -7.7% | — | |
| $2.92 | $448.11M | -1.62 | 25.39% | -157.32% | -196.63% | — | |
| $59.03 | $5.69B | -9.12 | -89.97% | -3368.72% | -24.39% | — | |
| $12.69 | $1.42B | -3.33 | 16.92% | -672.16% | -57.79% | — | |
| $3.54 | $639.39M | -2.62 | 55.28% | -4613.11% | -188.27% | — |
Korro Bio, Inc. (KRRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Korro Bio, Inc. (KRRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 11, 2026·SEC
May 19, 2026·SEC
Get notified when KRRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Korro Bio, Inc. (KRRO) stock FAQ — growth, dividends, profitability & financials explained
Korro Bio, Inc. (KRRO) reported $2.4M in revenue for fiscal year 2025.
Korro Bio, Inc. (KRRO) grew revenue by 181.5% over the past year. This is strong growth.
Korro Bio, Inc. (KRRO) reported a net loss of $106.6M for fiscal year 2025.
Korro Bio, Inc. (KRRO) has a return on equity (ROE) of -110.7%. Negative ROE indicates the company is unprofitable.
Korro Bio, Inc. (KRRO) had negative free cash flow of $84.4M in fiscal year 2025, likely due to heavy capital investments.
